EUVIMEDEUVIMED entdecken
Crossref

Unlocking adult T‐cell leukemia/lymphoma's epigenetic secrets: delving into the mechanism and impact of EZH1 /2 inhibition

Paniz Tavakoli Shirazi, Megan J Bywater

Immunology & Cell Biology · 2024

DOI: 10.1111/imcb.12748 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunology & Cell Biology, 2024. Verfasst von Paniz Tavakoli Shirazi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia. Hauptthemen laut MEDLINE: Epigenesis, Genetic, Histones, Leukemia-Lymphoma, Adult T-Cell. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 11 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epigenetic modifications, particularly through methylation of DNA packaging histones, play a pivotal role in controlling gene expression. Aberrant patterns of histone methylation have been associated with the development and progression of hematological malignancies. Unraveling the impact of aberrant histone marks on gene expression and leukemogenesis has spurred a concerted effort to develop clinically effective epigenetic therapies. In malignancies associated with the accumulation of histone H3 lysine trimethylation (H3K27me3), one such intervention involves preventing the deposition of this repressive histone mark by inhibiting the histone‐modifying enzymes EZH1 and EZH2. While inhibition of EZH1/2 has demonstrated efficacy in both preclinical studies and clinical trials in various cancers, studies delineating the dynamic effect of EZH1/2 inhibition on H3K27me3 and disease relapse in clinical samples are lacking. In a recent publication, Yamagishi et al. explore how responses of a patient with adult T‐cell leukemia/lymphoma to valemetostat, an EZH1/2 inhibitor, are associated with changes in H3K27me3, chromatin accessibility and gene expression, and how these changes can be circumvented in relapsed disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epigenesis, GeneticHistonesLeukemia-Lymphoma, Adult T-CellAnimalsHumansEnhancer of Zeste Homolog 2 ProteinPolycomb Repressive Complex 2

Stichwörter der Autor:innen

Adult T‐cell leukemia/lymphomaDNA methylationEZH1/2 inhibitionH3K27me3 markPRC2 mutationsresistance mechanisms

Substanzen

Enhancer of Zeste Homolog 2 ProteinEZH1 protein, humanEZH2 protein, humanHistonesPolycomb Repressive Complex 2

Autor:innen und Institutionen

  • Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
  • The University of Queensland, St Lucia, Brisbane, QLD, Australia.

Zitieren

APA

Tavakoli Shirazi, P., & Bywater, M. J. (2024). Unlocking adult T‐cell leukemia/lymphoma's epigenetic secrets: delving into the mechanism and impact of EZH1 /2 inhibition. Immunology & Cell Biology. https://doi.org/10.1111/imcb.12748

Vancouver

Tavakoli Shirazi P, Bywater MJ. Unlocking adult T‐cell leukemia/lymphoma's epigenetic secrets: delving into the mechanism and impact of EZH1 /2 inhibition. Immunology & Cell Biology. 2024. doi:10.1111/imcb.12748

BibTeX
@article{TavakoliShirazi2024,
  author = {Tavakoli Shirazi, Paniz and Bywater, Megan J},
  title = {Unlocking adult T‐cell leukemia/lymphoma's epigenetic secrets: delving into the mechanism and impact of EZH1 /2 inhibition},
  journal = {Immunology & Cell Biology},
  year = {2024},
  doi = {10.1111/imcb.12748}
}
Kostenlos starten →